CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Viralytics Ltd. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Viralytics Ltd.
SE 305 L 3, 66 Hunter St
Phone: +61 299884000p:+61 299884000 SYDNEY, NSW  2000  Australia Fax: +61 280686038f:+61 280686038
This company was Merged or Acquired on 6/20/2018.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Viralytics Limited is a biotechnology company. The Company focuses on the development and commercialization of oncolytic immunotherapies that harness the power of certain viruses to preferentially infect and kill cancer cells. The principal activity of the Company is clinical and preclinical development of its lead product, CAVATAK. CAVATAK is a formulation of the common cold Coxsackievirus Type A21. CAVATAK binds to specific receptor proteins expressed on a range of tumor cell types, and acts to destroy local, as well as metastatic cancer cells through cell lysis and the generation of a specific immune response against the cancer cells. CAVATAK is a naturally occurring, genetically unaltered virus with activity in a range of cancer types, including, but not limited to melanoma, prostate, lung, and bladder cancers. CAVATAK is being evaluated in Phase I and II clinical trials, both as an intratumoural and intravenous agent.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20176/30/2017Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Paul A.Hopper 5/1/2013 9/4/2008
Chief Financial Officer Robert C.Vickery 41
Chief Science Officer DarrenShafren 11/18/2008 12/14/2004
4 additional Officers and Directors records available in full report.

Business Names
Business Name
Psiron Limited
Psiron Ltd
Viralytics Ltd.
VLA
VRACY

General Information
Stock Exchange: ASX
Fax Number: +61 280686038


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023